Clinical trials: Sorafenib
Metastatic Breast Cancer
Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment
AIM OF STUDY Primary Efficacy Variable: The primary study objective is the proof of efficacy, measured by progression free survival (PFS) in the treatment of metastatic or locally inoperable recurrent breast cancer.
- Trial name
- PASO (NCT01320111)
- Testing
- Paclitaxel and Sorafenib, Paclitaxel
- Where
- Germany
- Volunteers
- 59 people
- Sponsor
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Carcinoma, Renal Cell
Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma
This is an observational study which will investigate the use of Nexavar as first targeted therapy in patients with advanced renal cell carcinoma.
- Trial name
- NEXTAR (NCT01508364)
- Testing
- Sorafenib (Nexavar, BAY 43-9006)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Bayer
Carcinoma, Hepatocellular
Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Nexavar for unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT01411436
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- Japan
- Volunteers
- 1,637 people
- Sponsor
- Bayer
Ovarian Neoplasm, Fallopian Tube Cancer
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
Background: Sorafenib and bevacizumab are anti-cancer drugs that work by targeting the blood vessels that allow tumors to grow. Using the two drugs together may more effectively block the formation of blood vessels that feed…
- Conditions
- Ovarian Neoplasm, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT00436215
- Testing
- Bevacizumab, BAY 43-9006
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer
Sorafenib has demonstrated in vivo anti-tumor efficacy. This trial will evaluate the safety and preliminary efficacy of sorafenib following chemoradiation in locally advanced NSCLC.
- Trial name
- NCT00417248
- Testing
- Cisplatin, Etoposide, Radiotherapy
- Where
- 8 sites in United States
- Volunteers
- 8 people
- Sponsor
- Nasser Hanna, M.D.
Carcinoma, Hepatocellular
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the safety and efficacy of doxorubicin plus sorafenib versus doxorubicin plus placebo in patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT00108953
- Testing
- Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin
- Where
- 28 sites in United States, Argentina and 4 more
- Volunteers
- 96 people
- Sponsor
- Bayer
Hepatocellular Cancer
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
The PI is studying if sorafenib/hydroxychloroquine (HCQ) will have improved efficacy when compared to sorafenib alone and in patients progressing of sorafenib the addition of HCQ would lead to disease stability in patients with…
- Trial name
- NCT03037437
- Testing
- Sorafenib (SOR), Hydroxychloroquine (HCQ)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer
This phase I/II trial studies the side effects and best dose of sorafenib tosylate and bevacizumab and to see how well they work in treating patients with advanced kidney cancer.
- Conditions
- Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma
- Trial name
- NCT00126503
- Testing
- Bevacizumab, Sorafenib Tosylate, Pharmacological Study
- Where
- 5 sites in United States
- Volunteers
- 73 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors
Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
The goal of this clinical research study is to find the highest tolerable dose of valproic acid in combination with either dasatinib, erlotinib hydrochloride, lapatinib, lenalidomide, sorafenib, or SU011248 (sunitinib malate)…
- Trial name
- NCT00495872
- Testing
- Dasatinib, Erlotinib, Lapatinib
- Where
- United States
- Volunteers
- 204 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Hepatocellular Carcinoma
Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
This clinical trial studies sorafenib tosylate in treating patients with liver cancer that cannot be removed by surgery. Sorafenib tosylate may block some of the enzymes needed for tumor cell growth.
- Conditions
- Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Hepatocellular Carcinoma, Stage III Childhood Hepatocellular Carcinoma, Stage IIIA Hepatocellular Carcinoma
- Trial name
- NCT02072486
- Testing
- Laboratory Biomarker Analysis, Sorafenib Tosylate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Roswell Park Cancer Institute
Hepatocellular Carcinoma
The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction
Many investigators have studied for prevention and care of Hand-Foot Skin Reaction(HFSR), and urea cream is typical representative.
- Trial name
- NCT03212625
- Testing
- Urea Cream 20%
- Where
- South Korea
- Volunteers
- 288 people
- Sponsor
- Korea University Guro Hospital
Hepatocellular Carcinoma, Recurrence
Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection
This prospective multicenter non-randomized controlled study evaluates the efficacy and safety of treatment with Sorafenib (Nevaxar) in patients with hepatocellular carcinoma with microvascular invasion after radical resection…
- Trial name
- NCT02867280
- Testing
- Sorafenib
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Sun Yat-sen University
Renal Cell Carcinoma
Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma
The goal of this clinical research study is to learn the effectiveness of sorafenib combined with gemcitabine plus cisplatin in the treatment of patients with locally advanced or metastatic collecting duct carcinoma(CDC) of the…
- Trial name
- NCT01762150
- Testing
- Sorafenib, Gemcitabine, Cisplatin
- Where
- 5 sites in China
- Volunteers
- 26 people
- Sponsor
- Peking University Cancer Hospital & Institute
Advanced Hepatocellular Carcinoma
Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma
This study is establish whether INC280 is safe and has beneficial effects in patients with advanced hepatocellular carcinoma known to have dysregulation of c-MET pathway and whose disease progressed while on, or after, treatment…
- Trial name
- NCT01964235
- Testing
- INC280
- Where
- 15 sites in United States, Australia and 5 more
- Sponsor
- Novartis Pharmaceuticals
Adenocarcinoma of the Prostate
A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer
Purpose: To determine the efficacy of BAY 43-9006 in combination with bicalutamide in patients with chemo-naïve hormone-refractory prostate cancer.
- Trial name
- NCT00430235
- Testing
- BAY 43-9006
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- British Columbia Cancer Agency
Colorectal Neoplasms
Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer
The purpose of this study is to determine whether sorafenib in combination with chemotherapy has a positive effect on time to progression of the tumor or death for the treatment of large bowel cancer that has already progressed…
- Trial name
- FOSCO (NCT00889343)
- Testing
- Sorafenib, Oxaliplatin or Irinotecan, Leucovorin
- Where
- 57 sites in Germany
- Volunteers
- 101 people
- Sponsor
- AIO-Studien-gGmbH
Cancer of the Cervix
A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer
This will be a multi-institution, single-arm, open-label, phase I/II trial. Eligible patients will have pathologically-proven T1b-3b, N0/1, M0 epithelial carcinoma of the cervix.
- Trial name
- NCT00510250
- Testing
- Sorafenib, Cisplatin, Radiation
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- University Health Network, Toronto
Ovarian Cancer
Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer
It is assumed, that the patients of the standard arm show a median progression-free survival time of 4.4 months those of the experimental arm of at least 6.9 months.
- Trial name
- TRIAS 2009 (NCT01047891)
- Testing
- Sorafenib
- Where
- Germany
- Volunteers
- 174 people
- Sponsor
- JSehouli
Leukemia, Acute Myeloid Leukemia
Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
There are 2 parts to this study: Part 1 (dose escalation) and Part 2 (dose expansion). The goal of Part 1 of this clinical research study is to find the highest tolerated dose of the combination of selinexor (KPT-330) and…
- Trial name
- NCT02530476
- Testing
- Selinexor, Sorafenib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma
Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE
To evaluate safety and efficacy of combined hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin and sorafenib in hepatocellular carcinoma (HCC) refractory to transarterial…
- Trial name
- NCT03722498
- Testing
- HAIC of FOLFOX, Sorafenib
- Where
- 3 sites in China
- Sponsor
- Sun Yat-sen University